Keyphrases
Chronic Hepatitis B
72%
Hepatitis B Virus
69%
Hepatitis B
63%
North America
53%
Hepatitis B e Antigen (HBeAg)
42%
Interferon-α (IFN-α)
42%
Hepatitis C Virus
31%
Cirrhosis
30%
Hepatocellular Carcinoma
26%
Liver Transplantation
25%
Antiretroviral Therapy
25%
AIDS/HIV
24%
Hepatitis B Surface Antigen (HBsAg)
23%
Hepatitis C
20%
Human Immunodeficiency Virus Infection
18%
Hepatitis B Core-related Antigen
18%
Hepatitis
18%
Liver Transplant Recipients
17%
Virus Hepatitis
16%
Liver Disease
16%
Alanine Aminotransferase
15%
Chronic Hepatitis B Virus Infection
15%
Hepatitis A
14%
Fibrosis
14%
Chronic Hepatitis B Virus
14%
Chronic Hepatitis C
14%
Recombinant Human
14%
Tenofovir
14%
Liver Biopsy
14%
Hepatitis C Virus Infection
13%
Liver
13%
Multi-ethnic
13%
Prospective Cohort Study
12%
Hepatic Steatosis
12%
Chronic Hepatitis
12%
Viral Hepatitis
12%
Hepatitis B Virus DNA
12%
Chronic Viral Hepatitis
12%
Tenofovir Disoproxil Fumarate
11%
Orthotopic Liver Transplantation
11%
Clinical Outcomes
11%
Fatty Liver Disease
10%
Ribavirin
10%
Interferon Therapy
10%
Pegylated Interferon
10%
Hepatitis B Virus Genotype
10%
Virologic
9%
Chronic Liver Disease
9%
Alanine Aminotransferase Level
9%
Advanced Fibrosis
9%
Pharmacology, Toxicology and Pharmaceutical Science
Hepatitis B Virus
100%
Hepatitis B
74%
Chronic Hepatitis B
68%
HIV
45%
Hepatitis B(e) Antigen
37%
Virus Hepatitis
35%
Interferon
27%
Fibrosis
25%
Infection
21%
Fatty Liver
21%
Hepatitis B Antigen
21%
Mixed Infection
18%
Liver Cell Carcinoma
18%
Hepatitis C
17%
Hepatitis A
17%
Alanine Aminotransferase
16%
Prevalence
15%
Alpha Interferon
14%
Hepatitis C Virus
14%
Ribavirin
14%
Chronic Hepatitis C
14%
Tenofovir
13%
Liver Cirrhosis
13%
Aminotransferase
13%
Peginterferon
12%
Tenofovir Disoproxil
12%
Combination Therapy
12%
Chronic Hepatitis
12%
Liver Disease
12%
Virus Infection
11%
Antivirus Agent
11%
Clinical Trial
10%
Peginterferon Alpha
10%
End Stage Liver Disease
9%
Virus DNA
9%
Virus RNA
9%
Antiviral Therapy
8%
Cohort Study
8%
Delta Agent Hepatitis
8%
Lamivudine
8%
Hepatitis C Virus Genotype 1
8%
Tolerability
8%
Vaccine
8%
Placebo
8%
Side Effect
7%
Disease Activity
7%
Steatosis
6%
Diseases
6%
Survival Rate
6%
Ethanol
5%
Medicine and Dentistry
Hepatitis B Virus
74%
Chronic Hepatitis B
67%
Hepatitis B
54%
Human Immunodeficiency Virus
34%
Hepatitis B(e) Antigen
32%
Diseases
26%
Liver Cirrhosis
22%
Fibrosis
22%
Fatty Liver
21%
Hepatitis B Antigen
21%
Hepatitis C Virus
21%
Liver Disease
20%
Antiviral Therapy
19%
Liver Graft
18%
Prevalence
18%
Liver Transplantation
18%
Hepatitis C
18%
Alanine Aminotransferase
18%
Hepatocellular Carcinoma
17%
Mixed Infection
15%
Virus
14%
Infection
14%
Liver Biopsy
13%
Steatohepatitis
13%
Antiretroviral Therapy
12%
Biopsy Technique
11%
Transplantation
10%
Peginterferon
10%
Tenofovir
9%
Steatosis
8%
Prospective Cohort Study
8%
Ribavirin
8%
Chronic Hepatitis
8%
Virus Infection
8%
Model For End Stage Liver Disease Score
8%
Cohort Analysis
7%
Tenofovir Disoproxil
7%
Hepatitis Virus
7%
Liver Injury
6%
Alcohol Consumption
6%
Chronic Hepatitis C
6%
Disease Severity
5%
Model for End-Stage Liver Disease
5%
Nonalcoholic Fatty Liver
5%
Graft Survival
5%
Disease Exacerbation
5%
Diagnosis
5%
Disease Activity
5%
Immunohistochemistry
5%
Liver Fibrosis
5%